Table 1.
Clinical information
| Number | Gender | Age | Stage | 18.2 express | Dose | PFS (d) | OS (d) | Clinical evaluation | Peritoneal dropsy |
|---|---|---|---|---|---|---|---|---|---|
| Case1 | Female | 63 | pT4aN0 | 2+, 80% | 2.5∗108 | 58 | 85 | PD | PD’ |
| Case2 | Male | 45 | pT4aN3bM1 | 2+, 70% | 2.5∗108 | 143 | 143 | PD | PD’ |
| Case3 | Male | 59 | cTxNxM1 | 3+, 90% | 2.5∗108 | 78 | 91 | PD | PR’ |
| Case4 | Female | 57 | cT4aN2M1 | 3+, 90% | 2.5∗108 | 54 | 140 | PD | PR’ |
| Case5 | Female | 31 | pT3N1 | 3+, 90% | 2.5∗108 | 596 | 680 | PR | PR’ |
PFS, progression-free survival; OS: overall survival; PD, progressive disease; PR, partial response.